IDH1 and glioma: IDH1/2 mutations promote the development of various cancers, such as lymphoma and glioma; ivosidenib, which targets mutated IDH1, and enasidenib, which targets IDH2, were approved for marketing and use in the treatment of acute myeloid leukemia in 2017 and 2018, respectively [292,293,294].